Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge
about
Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in ThailandNonpathogenic simian immunodeficiency virus infectionsThe simian immunodeficiency virus targets central cell cycle functions through transcriptional repression in vivoAssociation of TLR7 variants with AIDS-like disease and AIDS vaccine efficacy in rhesus macaquesDifferent Vaccine Vectors Delivering the Same Antigen Elicit CD8+ T Cell Responses with Distinct Clonotype and Epitope SpecificityA phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)A DNA vaccine encoding multiple HIV CD4 epitopes elicits vigorous polyfunctional, long-lived CD4+ and CD8+ T cell responsesPriming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responsesNovel viral vectored vaccines for the prevention of influenza.DNA encoding an HIV-1 Gag/human lysosome-associated membrane protein-1 chimera elicits a broad cellular and humoral immune response in Rhesus macaques.Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239.A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).Induction of neutralizing antibody response against four dengue viruses in mice by intramuscular electroporation of tetravalent DNA vaccines.Acute mucosal pathogenesis of feline immunodeficiency virus is independent of viral dose in vaginally infected cats.Immunologic and virologic events in early HIV infection predict subsequent rate of progression.HIV vaccines: lessons learned and the way forward.A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes.HIV-associated chronic immune activation.Challenges in the development of an HIV-1 vaccine.HIV-1 adenoviral vector vaccines expressing multi-trimeric BAFF and 4-1BBL enhance T cell mediated anti-viral immunityIL-15 delays suppression and fails to promote immune reconstitution in virally suppressed chronically SIV-infected macaques.Low levels of SIV infection in sooty mangabey central memory CD⁴⁺ T cells are associated with limited CCR5 expression.Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.TLR agonists and/or IL-15 adjuvanted mucosal SIV vaccine reduced gut CD4⁺ memory T cell loss in SIVmac251-challenged rhesus macaques.Understanding the failure of CD8+ T-cell vaccination against simian/human immunodeficiency virus.The antiviral efficacy of simian immunodeficiency virus-specific CD8+ T cells is unrelated to epitope specificity and is abrogated by viral escape.HIV DNA Vaccine: Stepwise Improvements Make a Difference.Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine.SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection.Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary.Estimating the infectivity of CCR5-tropic simian immunodeficiency virus SIV(mac251) in the gut.Application of Long-term cultured Interferon-γ Enzyme-linked Immunospot Assay for Assessing Effector and Memory T Cell Responses in Cattle.New paradigms for HIV/AIDS vaccine development.A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challengePreexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccineGlycosylation of simian immunodeficiency virus influences immune-tissue targeting during primary infection, leading to immunodeficiency or viral controlHSV-1 amplicon vectors elicit polyfunctional T cell responses to HIV-1 Env, and strongly boost responses to an adenovirus prime.CD4 T follicular helper cell dynamics during SIV infectionAdjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus.
P2860
Q21134955-60235DE6-3FE0-417D-BFBB-878CD3915CAFQ27004065-D09F08CB-6EA6-4122-9F41-7A26C9573835Q27317391-38033552-B3DF-48D0-A9AE-0EA4487D03FAQ27318249-2503AFCE-F475-46C1-8D12-7B43DC0371E7Q27646554-9E9ACBD6-FA2D-4772-82E7-951A40EE6A9CQ28741673-6273CD5C-2A2A-498F-83D7-69E87BA44D9BQ28742853-3C22AB28-B526-4AA8-9B04-A89E8E989890Q28749120-F3C7C6FF-5C3C-4022-9991-7994D7416F49Q30418570-185A412E-C6CB-4CA4-9F46-AC7DC355D84DQ33268303-ED0516F9-0E46-4576-A58F-4DB45B3BE268Q33402455-7ADC97A6-B308-47C7-9E01-21CB5232E761Q33611719-0C280F70-9863-4D8A-AC50-A3661C554612Q33699057-0F3C2F89-68C3-4C88-99FD-4F29AE1E840DQ33715758-E6CEC3F1-9B9F-4F02-88A2-A5A63C0BBACEQ34127870-9BF1A0B4-1272-4617-8559-2C582C59ACDFQ34342558-06D8FCC4-9320-4DD2-B30E-A4456EB3423EQ34369139-7C033790-EDF5-45E7-B6D4-52645DD1C4BAQ34612545-D29ED17F-D740-47F4-BB43-32CF60D4EF7FQ34653277-2B889251-6A08-4346-91E3-15DF13068EB5Q34657290-F4D27A35-7F12-4CCE-8A69-2BB1EC1CC5DAQ35108680-58B8E10B-72CB-47EF-A1A7-B127FBF72CCBQ35197395-2FCA514F-6B8E-47BC-87B0-933659035D7BQ35658578-0ACE2786-456D-40BC-A9B7-BA797166A072Q35661163-751E1D3B-FD0A-4FBE-A154-D0891FB39018Q35672335-2C5BB4A2-D8AD-470F-9AF4-633E40519820Q35784787-727E35D3-B3ED-48DB-B4A8-B772A93C2C15Q35784928-A9CD1E85-5BAE-48FC-A73F-6FABEAC23E97Q35826742-6494514D-AE07-4EA6-8FF5-DC91ABF86AA4Q35857531-721B0528-6B69-4FA7-BF12-30019B92DBDBQ35901710-7FF7A692-38E9-42F7-B89E-33A429395AFCQ35904496-D0E7C747-0F7C-4B15-8EC8-A47E8E893BEFQ35947552-7DFA0F6B-83AD-40EF-8E5A-B2BBD0E77DB6Q35982511-0F7A7408-6DB2-433E-B043-818300D79327Q36011269-E3A30BAF-EF0E-4488-829B-B808D3CD3946Q36024470-DDD26DBB-753D-4902-B358-8F439C868B65Q36141586-78D7195E-E5C8-473D-A474-0A4C7D3CFE83Q36155024-5458CF59-9170-4325-908C-6C08DFFEF8AAQ36166161-8A4D39EF-CFD8-49E3-B2C7-34336C2E4BD5Q36190736-192CF569-17FA-4137-BBAB-7266DF8F41FFQ36229051-4E2B5F42-5279-4085-B198-C00C62053491
P2860
Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Vaccination preserves CD4 memo ...... munodeficiency virus challenge
@ast
Vaccination preserves CD4 memo ...... munodeficiency virus challenge
@en
type
label
Vaccination preserves CD4 memo ...... munodeficiency virus challenge
@ast
Vaccination preserves CD4 memo ...... munodeficiency virus challenge
@en
prefLabel
Vaccination preserves CD4 memo ...... munodeficiency virus challenge
@ast
Vaccination preserves CD4 memo ...... munodeficiency virus challenge
@en
P2093
P2860
P50
P356
P1476
Vaccination preserves CD4 memo ...... munodeficiency virus challenge
@en
P2093
Alicia Buckler-White
Daniel C Douek
Mario Roederer
Norman L Letvin
P2860
P304
P356
10.1084/JEM.20060657
P407
P577
2006-05-30T00:00:00Z